기면증 치료 시장 : 약제 클래스별, 질환 유형, 연령층, 제형, 유통 채널별 - 세계 예측(2026-2032년)

The Narcolepsy Treatment Market is projected to grow by USD 5.39 billion at a CAGR of 8.00% by 2032.

Narcolepsy Treatment Market Introduction

Narcolepsy treatment is moving from symptom control toward precision sleep medicine, with care models focused on excessive daytime sleepiness, cataplexy, disrupted nighttime sleep, hypnagogic hallucinations, sleep paralysis, and long-term functional impairment. Clinically recognized narcolepsy is commonly categorized as type 1, associated with cataplexy and hypocretin deficiency, and type 2, generally without cataplexy.

The market is shaped by proven therapies such as oxybate formulations, wake-promoting agents, stimulants, selective histamine H3 receptor inverse agonists, and antidepressants used for cataplexy management. Growth is supported by higher diagnosis rates, improved sleep-lab access, expanded telehealth pathways, and the need for safer, longer-acting, lower-sodium, and adherence-friendly treatment options aligned with evidence-based sleep medicine standards.

Transformative Shifts in the Narcolepsy Treatment Landscape

The narcolepsy treatment landscape is undergoing a meaningful shift as clinicians move beyond broad stimulant-based management toward targeted, evidence-led regimens. The approval and adoption of therapies such as sodium oxybate, low-sodium oxybate, solriamfetol, and pitolisant have broadened clinical options for excessive daytime sleepiness and cataplexy while increasing competition around safety, dosing convenience, drug interaction profiles, and patient-reported outcomes.

Transformative change is also occurring in diagnosis and care delivery. Long diagnostic delays remain documented in narcolepsy, often spanning several years, which is driving investment in sleep-specialist networks, digital screening tools, validated sleep questionnaires, and patient education. Payers are increasingly evaluating real-world evidence, adherence, sodium burden, abuse potential, controlled-substance requirements, and total cost of care when determining access.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a practical enabler across the narcolepsy treatment value chain. AI-assisted analysis of polysomnography, multiple sleep latency testing, actigraphy, wearable sleep data, and electronic health records can help identify patients with persistent excessive daytime sleepiness, reduce diagnostic friction, and support earlier referral to sleep specialists.

For drug developers and providers, AI strengthens clinical trial design, patient stratification, pharmacovigilance signal detection, adherence monitoring, and real-world outcomes assessment. Its cumulative impact is strongest where algorithms are clinically validated, explainable, privacy-compliant, and integrated with physician oversight, because narcolepsy diagnosis still depends on structured clinical history, objective sleep testing, and exclusion of other sleep disorders such as obstructive sleep apnea, insufficient sleep syndrome, and circadian rhythm disorders.

Key Regional Insights: Asia-Pacific, North America, Europe, Latin America, Middle East, and Africa

North America remains a leading region for narcolepsy treatment because of established sleep medicine infrastructure, specialty pharmacy networks, favorable awareness, patient advocacy, and early access to branded therapies approved by the U.S. Food and Drug Administration. Europe benefits from national health systems, European Medicines Agency oversight, clinical guideline adoption, and strong pharmacovigilance expectations, although reimbursement pathways and health technology assessment requirements differ across countries.

Asia-Pacific is gaining strategic relevance as China, Japan, India, South Korea, and Australia expand sleep disorder diagnosis, specialist access, and neurology-focused care. Japan has long-standing sleep medicine expertise, while China and India present substantial underdiagnosis challenges linked to uneven access to sleep laboratories and trained specialists. Latin America shows improving awareness but faces inconsistent access to objective sleep testing and specialty medicines. The Middle East is supported by premium healthcare investment in GCC markets and growing demand for advanced neurology and sleep services, while Africa remains constrained by limited diagnostic capacity, workforce shortages, and affordability barriers, creating opportunities for education, screening, and scalable care models.

Key Group Insights: ASEAN, GCC, EU, BRICS, G7, and NATO

Across ASEAN, rising healthcare investment, urban sleep-clinic development, and digital health adoption are improving the identification of sleep disorders, although specialist shortages and variable reimbursement remain barriers to consistent narcolepsy treatment access. GCC countries are prioritizing advanced hospitals and specialty care, making them attractive for premium narcolepsy therapies, physician training, diagnostic partnerships, and regulated import pathways for innovative medicines.

The European Union provides a structured environment for evidence-based prescribing, centralized regulatory review, health technology assessment, and post-marketing safety surveillance. BRICS markets combine large patient pools with variable reimbursement maturity and uneven sleep-laboratory availability, creating demand for cost-sensitive access strategies and clinician education. G7 markets lead in therapeutic innovation, reimbursement scrutiny, pharmacovigilance, and real-world evidence generation, while NATO countries largely overlap with advanced healthcare systems where supply continuity, controlled-substance compliance, cybersecurity, and regulatory resilience influence market access.

Key Country Insights Across Major Narcolepsy Treatment Markets

The United States is the most influential narcolepsy treatment market due to FDA-approved branded therapies, specialty distribution, controlled-substance monitoring, payer management, and strong patient advocacy. Canada emphasizes evidence-based reimbursement, specialist-led prescribing, and provincial formulary evaluation, while Mexico and Brazil are expanding awareness but continue to face affordability, uneven diagnosis, and limited access to advanced specialty medicines.

In Europe, the United Kingdom, Germany, France, Italy, and Spain show strong clinical capability but differ in health technology assessment, reimbursement timelines, and regional prescribing pathways. Russia presents access complexity linked to regulatory, supply, and geopolitical factors. In Asia-Pacific, China and India offer large underdiagnosed populations and growing neurology infrastructure, Japan has established sleep medicine expertise and recognized narcolepsy research activity, South Korea combines digital healthcare capacity with specialty care, and Australia benefits from structured clinical pathways, public-private healthcare coverage, and high awareness of sleep disorders.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize differentiated clinical value, including lower sodium exposure, simplified dosing, improved nighttime sleep, reduced cataplexy burden, durable wakefulness, and measurable functional outcomes. Market access strategies should be supported by real-world evidence demonstrating adherence, safety, quality-of-life improvement, productivity gains, and reduced healthcare utilization.

Organizations should also invest in diagnostic partnerships with sleep centers, neurologists, psychiatrists, pulmonologists, pediatric specialists, and primary care networks to shorten the patient journey. Scalable education for clinicians and patients, responsible AI-enabled screening, pharmacovigilance excellence, controlled-substance stewardship, and region-specific pricing models will be essential to expand access without compromising clinical standards.

Research Methodology

This executive summary is developed using a structured secondary-research methodology focused on verified public sources, including regulatory databases, clinical guidelines, peer-reviewed literature, pharmacovigilance resources, and recognized healthcare policy references. The analysis considers approved therapies, clinical use patterns, diagnosis pathways, reimbursement dynamics, safety requirements, and regional healthcare infrastructure.

Insights are triangulated across epidemiology, treatment availability, policy environments, clinical practice guidance, and market access indicators. No unverified market-size, market-share, or growth-rate claims are used; instead, the summary emphasizes evidence-backed industry drivers, barriers, and strategic implications relevant to narcolepsy treatment stakeholders.

Conclusion

The narcolepsy treatment market is advancing as innovation, diagnosis improvement, and patient-centered care reshape therapeutic decision-making. Established and emerging medicines are competing on efficacy, safety, convenience, sodium exposure, abuse-risk management, and long-term value, while digital tools and AI are improving the ability to identify and support patients earlier.

Future leadership will depend on credible evidence, equitable access, regional execution, and collaboration across sleep medicine ecosystems. Organizations that align product differentiation with diagnostic enablement, payer expectations, regulatory requirements, and patient outcomes will be best positioned in the evolving narcolepsy treatment landscape.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Narcolepsy Treatment Market, by Drug Class

• 7.1. Antidepressants
• 7.2. Orexin Receptor Agonists
• 7.3. Sodium Oxybate
• 7.4. Stimulants

8. Narcolepsy Treatment Market, by Disorder Type

• 8.1. Narcolepsy Type 1
• 8.2. Narcolepsy Type 2

9. Narcolepsy Treatment Market, by Age Group

• 9.1. Adults
• 9.2. Geriatrics
• 9.3. Pediatrics

10. Narcolepsy Treatment Market, by Dosage Form

• 10.1. Tablets
• 10.2. Capsules
• 10.3. Oral Solutions

11. Narcolepsy Treatment Market, by Distribution Channel

• 11.1. Hospital Pharmacies
• 11.2. Online Pharmacies
• 11.3. Retail Pharmacies

12. Narcolepsy Treatment Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Narcolepsy Treatment Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Narcolepsy Treatment Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Alkermes plc
• 16.2. Amneal Pharmaceuticals, Inc.
• 16.3. Arena Pharmaceuticals, Inc.
• 16.4. Avadel Pharmaceuticals plc
• 16.5. Axsome Therapeutics, Inc.
• 16.6. Azurity Pharmaceuticals, Inc.
• 16.7. Bioprojet Pharma S.A.R.L.
• 16.8. Centessa Pharmaceuticals plc
• 16.9. Eli Lilly and Company
• 16.10. H. Lundbeck A/S
• 16.11. Harmony Biosciences Holdings, Inc.
• 16.12. Hikma Pharmaceuticals plc
• 16.13. Jazz Pharmaceuticals plc
• 16.14. Lupin Limited
• 16.15. NLS Pharmaceutics Ltd.
• 16.16. Novartis AG
• 16.17. Shionogi & Co., Ltd.
• 16.18. Sunovion Pharmaceuticals Inc.
• 16.19. Suven Life Sciences Limited
• 16.20. Takeda Pharmaceutical Company Limited
• 16.21. Teva Pharmaceutical Industries Ltd.
• 16.22. Theranexus SA
• 16.23. Torrent Pharmaceuticals Limited
• 16.24. Zevra Therapeutics, Inc.